Abstracts Archive - Page 2397 of 2605 - ACR Meeting Abstracts

Abstract Number: 490 • 2013 ACR/ARHP Annual Meeting
Does Low Disease Activity At Six Months Predict Remission At 12 Months In Rheumatoid Arthritis Patients Treated With Biologics In a Real–World Setting?
Philip Baer¹, William G. Bensen², Andrew Chow³, Rafat Y. Faraawi^4,5, Denis Choquette⁶, Isabelle Fortin⁷, John T. Kelsall⁸, Dalton E. Sholter⁹, Emmanouil Rampakakis^10,11, John S. Sampalis^10,11, Francois Nantel¹², Allen J. Lehman¹³, May Shawi¹⁴ and Susan M. Otawa¹³, ¹Private Practice, Scarborough, ON, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁷Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁸Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁹Rheumatology Associates, Edmonton, AB, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ¹²Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Remission is considered the treatment goal in the management of patients with rheumatoid arthritis (RA). The objective of this analysis was to determine if…
Abstract Number: 491 • 2013 ACR/ARHP Annual Meeting
Infection Risk Among Patients Receiving Concurrent Denosumab and Biologic Or Non-Biologic DMARD Therapy: An Analysis Of The Consortium Of Rheumatology Researchers Of North America (CORRONA) Registry
Vance J. Bray¹, Adam W. Bagley², Sterling G. West³, Carol J. Etzel⁴, Joel M. Kremer⁵ and Jason R. Kolfenbach⁶, ¹Denver Arthritis Clinic, Denver, CO, ²Internal Medicine, University of Colorado School of Medicine, Aurora, CO, ³Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Department of Epidemiology, UT MD Anderson, Houston, TX, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: RANKL is a cytokine member of the tumor necrosis family that mediates osteoclastic bone resorption. Denosumab prevents RANKL from activating RANK on the cell…
Abstract Number: 492 • 2013 ACR/ARHP Annual Meeting
Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase 2
Ruth Fritsch-Stork¹, Sandra Cardoso¹, Jasper Broen¹, Marian Groot-Koerkamp², Arno Concepcion¹, Floris Lafeber¹ and Johannes W.J. Bijlsma¹, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Molecular Cancer Research, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GC) have been a cornerstone of Rheumatoid arthritis (RA)-therapy for the last decades. However, about a third of RA-patients do not respond adequately.…
Abstract Number: 493 • 2013 ACR/ARHP Annual Meeting
A Real-World Risk Analysis Of Biological Treatment (Adalimumab and Etanercep) In Country With High Prevalence Of Tuberculosis and Hepatitis B/C
Ying-Ming Chiu¹, Chao-Hsiung Tang², Sheng-Tzu Hung³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Hsiao-Yi Lin⁵, ¹Changhua Christian Hospital, Changhua City, Taiwan, ²Taipei Medical University, Taipei, Taiwan, ³Formosa Biomedical Technology Corp., Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Immunology and Rheumatology, Dept of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: Biologics have been widely utilized in many rheumatic diseases. Risks associated with the use of biological treatments are revealed in many published studies. Nevertheless,…
Abstract Number: 494 • 2013 ACR/ARHP Annual Meeting
Autoantibody Profiles Predict Responsiveness To Methotrexate and Anti-TNF Therapy In Early Rheumatoid Arthritis
Petra Budde¹, Angelika Lueking¹, Carmen Theek¹, Peter Schulz-Knappe¹, Jacqueline Detert², Gerd Burmester³ and Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ³Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ⁴Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Novel therapeutic concepts in early rheumatoid arthritis (ERA) are aiming for an early intervention and effective control of disease activity reaching remission. Most current…
Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Axel Finckh¹, Florenzo Iannone², Juan Gomez Reino³, David Neto⁴, Elisabeth Lie⁵, Piet van Riel⁶, Merete Lund Hetland⁷, Karel Pavelka⁸, Carl Turesson⁹, Xavier Mariette¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ²D.I.M.I.M.P, Rheumatology Unit - University of Bari, Bari, Italy, ³Rheumatology Department, Hospital Clínico de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology, University of Geneva, Geneva, Switzerland, ⁵Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, ⁸Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁹Lund University, Malmö, Sweden, ¹⁰Paris-Sud University, Paris, France, ¹¹Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…
Abstract Number: 496 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Repeated Courses Of Rituximab In RA – Results From The Cererra Collaboration
Katerina Chatzidionysiou¹, Elisabeth Lie², Evgeny Nasonov³, Galina Lukina³, Merete Lund Hetland⁴, Ulrik Tarp⁵, Karel Pavelka⁶, Cem Gabay⁷, Dan Nordström⁸, Helena Canhao⁹, Matija Tomsic¹⁰, Piet van Riel¹¹, Juan Gomez-Reino¹², Ioan Ancuta¹³, Tore Kvien² and Ronald van Vollenhoven¹⁴, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³ARBITER, Institute of Rheumatology, Moscow, Russia, ⁴DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ⁸ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ⁹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ¹⁰Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, ¹¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹²Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹³Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ¹⁴Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose: Retreatment with rituximab (RTX) is common clinical practice, although several aspects regarding retreatment, such as frequency, need to be further elucidated. The aim of…
Abstract Number: 497 • 2013 ACR/ARHP Annual Meeting
Development Of a Novel Bispecific Therapeutic For Arthritic Diseases
Mathieu Ferrari¹, Shimobi Onuoha¹, Tahereh Kamalati², Daniele Sblattero³ and Costantino Pitzalis⁴, ¹Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London, London, United Kingdom, ²University College of London, London, United Kingdom, ³University of Eastern Piedmont, Novara, Italy, ⁴Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, QMUL, London, United Kingdom
Background/Purpose: Despite the obvious success of current biological agents for treatment of rheumatoid arthritis (RA), achievement of broader efficacy and improved safety profile remains an…
Abstract Number: 499 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Infliximab Or Adalimumab Vs Abatacept In Patients With Rheumatoid Arthritis and An Inadequate Response To Methotrexate: Attest-Ample Network Randomized Trial
Robin Christensen¹, Simon Tarp¹, Daniel Furst², Lars E. Kristensen³ and Henning Bliddal⁴, ¹Musculoskeletal Statistics Unit, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, ²David Geffen School of Medicine, University of California, Los Angeles, CA, ³Rheumatology, Department of Clinical Sciences, Lund, Section of Rheumatology, Lund University, Lund, Sweden, ⁴Department of Rheumatology, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark
Background/Purpose: Using combined data from the ATTEST [1] and AMPLE [2] study comparing infliximab and adalimumab with abatacept in patients with rheumatoid arthritis (RA), we…
Abstract Number: 500 • 2013 ACR/ARHP Annual Meeting
Fixed Versus On-Flare Retreatment With Rituximab In RA – Results From The Cererra Collaboration
Katerina Chatzidionysiou¹, Elisabeth Lie², Evgeny Nasonov³, Galina Lukina³, Merete Lund Hetland⁴, Ulrik Tarp⁵, Karel Pavelka⁶, Cem Gabay⁷, Dan Nordström⁸, Helena Canhao⁹, Matija Tomsic¹⁰, Piet van Riel¹¹, Juan Gomez-Reino¹², Ioan Ancuta¹³, Tore Kvien¹⁴ and Ronald van Vollenhoven¹⁵, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³ARBITER, Institute of Rheumatology, Moscow, Russia, ⁴DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ⁸ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ⁹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ¹⁰Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, ¹¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹²Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹³Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ¹⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose: The data on how to optimally retreat patients with RA with rituximab (RTX) have been limited so far. The aim of this analysis was…
Abstract Number: 460 • 2013 ACR/ARHP Annual Meeting
Comparative Efficacy Of Novel Disease-Modifying Antirheumatic Drugs As Monotherapy and In Combination With Methotrexate In Rheumatoid Arthritis Patients With An Inadequate Response To Traditional Disease-Modifying Antirheumatic Drugs: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W.J. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Department of Medical Specialities, University of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: To compare ACR responses of novel DMARDs as monotherapy or in combination with methotrexate (MTX), including subcutaneous (SC) abatacept and SC tocilizumab (TCZ), in…
Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Daniel Furst¹, Mei Liu², Jeffrey D. Greenberg³ and Joel M. Kremer⁴, ¹Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ²CORRONA, Inc, Southborough, MA, ³NYU Hospital for Joint Diseases, New York, NY, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…
Abstract Number: 462 • 2013 ACR/ARHP Annual Meeting
Reduced Response To Biologic Treatments in Rheumatoid Arthritis Patients Affected By Arterial Hypertension
Marco Antivalle¹, Michel Chevallard², Michele Battellino², Alberto Batticciotto³, Maria Chiara Ditto², Alessandra Mutti¹, Federica Rigamonti⁴, Valentina Varisco², Sara Bongiovanni², Fabiola Atzeni⁵ and Piercarlo Sarzi-Puttini⁶, ¹Rheumatology, L. Sacco University Hospital, Milano, Italy, ²Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, ³Rheumatology, Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milano, Italy, ⁵Rheumatology, Rheumatology Unit, L. Sacco University Hospital, MiIano, Italy, ⁶Rheumatology Unit, L. Sacco University Hospital, Milan, Italy
Background/Purpose: Several reports show that the presence of comorbidities negatively influences both functional status (1) and quality of life (2) in rheumatoid arthritis (RA). No…
Abstract Number: 463 • 2013 ACR/ARHP Annual Meeting
An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety
Aaron C. Garza Romero¹, Elie Donath¹, Hernan Osorno¹ and Suresh Kumar², ¹Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ²Rheumatology, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL
Background/Purpose: There are primarily six groups of biologic disease modifiers (BDM) for treatment of rheumatoid arthritis (RA): tumor necrosis factor inhibitors (infliximab (IFX), etanercept (ETN),…
Abstract Number: 464 • 2013 ACR/ARHP Annual Meeting
The Efficacy and Safety Of Tocilizumab Subcutaneous Versus Tocilizumab Intravenous, In Combination With Traditional Dmards In Patients With RA At 49 Weeks (SUMMACTA)
Gerd Burmester¹, Andrea Rubbert-Roth², Alain G. Cantagrel³, Stephen Hall⁴, Piotr Leszczynski⁵, Daniel Feldman⁶, Madura J. Rangaraj⁷, Georgia Roane⁸, Charles L. Ludivico⁹, Eduardo F. Mysler¹⁰, Chris Wells¹¹, Melanie Bennett¹¹ and Ivana Vranic¹¹, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Klinikum der Universität zu Köln, Köln, Germany, ³Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁴Emeritus Research, Malvern, Australia, ⁵Dept. of Rheumatology and Clinical Immunology, J. Strus Poznan Municipal Hospital, Poznan University of Medical Sciences, Poznan, Poland, ⁶Rheumatology, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁷Arthritis & Diabetes Clinic, Inc., Monroe, LA, ⁸Rheumatology Associates of South Carolina, Charleston, SC, ⁹East Penn Rheumatology Associates, PC, Bethleham, PA, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina, ¹¹Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: The efficacy and safety of subcutaneous tocilizumab (TCZ SC) were demonstrated in a 24 week (wk) randomized clinical trial (SUMMACTA). The cumulative safety, immunogenicity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].